Lifecore Biomedical Inc (LFCR)

Lifecore Biomedical Inc. is a healthcare company listed on NASDAQ as common stock. Through its subsidiaries, it operates as a contract development and manufacturing organization serving customers in the United States, Belgium, the Netherlands, and other international markets. The company supports the development and production of sterile injectable pharmaceutical and medical device products, including aseptic fill-finish work for syringes, vials, and cartridges. It also manufactures pharmaceutical-grade hyaluronic acid for bulk use and for inclusion in injectable formulations used in areas such as ophthalmic and orthopedic care. In addition, Lifecore provides development services that include analytical methods, formulation work, sterile filtration, scale-up activities, pilot and stability studies, process validation, and materials for clinical studies. The company was founded in 1965 and is headquartered in Chaska, Minnesota; it adopted the Lifecore Biomedical name in November 2022.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-LFCR
$4.46
-30.2% Downside
Overvalued
$6.28
-1.9% Downside
Fair
Good
0.0%
2.3x
242.4 M
432.9 M
35.3%
51.1%
-0.5
-13.9%
Valuation • Fair Value

Lifecore Biomedical Inc (NASDAQ-LFCR) Fair Value by Valuation Model

Review the available estimates for Lifecore Biomedical Inc (NASDAQ-LFCR), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$4.46

Estimated downside of 30.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.86

Discounted cash flow valuation reference.

Comps Fair Value

$4.07

Comparable-company valuation reference.

Analyst Price Target

$6.28

Analysts imply downside of 1.9%.

How to read these valuation models

Use the 5 available valuation references for Lifecore Biomedical Inc (NASDAQ-LFCR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Lifecore Biomedical Inc (NASDAQ-LFCR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

106.5 M

Current operating scale indicator.

Revenue Forecast

121.5 M

Forward revenue estimate.

EBITDA

4.168 M

Current operating profitability reference.

EBITDA Forecast

22.854 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Lifecore Biomedical Inc (NASDAQ-LFCR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Lifecore Biomedical Inc (NASDAQ-LFCR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.07

No elevated caution signal from this screen.

Altman Z-Score

-0.5

Lower score that deserves closer risk review.

FCF / Net Income

-13.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Lifecore Biomedical Inc (NASDAQ-LFCR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Lifecore Biomedical Inc (NASDAQ-LFCR)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Lifecore Biomedical Inc (NASDAQ-LFCR). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Lifecore Biomedical Inc (NASDAQ-LFCR) Stock Forecast & Technical Outlook

Review Lifecore Biomedical Inc (NASDAQ-LFCR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Lifecore Biomedical Inc (NASDAQ-LFCR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Lifecore Biomedical Inc (NASDAQ-LFCR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Lifecore Biomedical Inc (NASDAQ-LFCR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Lifecore Biomedical Inc (NASDAQ-LFCR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Lifecore Biomedical Inc (NASDAQ-LFCR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Lifecore Biomedical Inc (NASDAQ-LFCR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Lifecore Biomedical Inc (NASDAQ-LFCR) has a Hold consensus, with 0 buy, 5 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 5
Sell 0
FAQ • Fast Investor Answers

Lifecore Biomedical Inc (NASDAQ-LFCR) Stock FAQ

Data-supported answers about Lifecore Biomedical Inc (NASDAQ-LFCR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$4.46
Estimated downside 30.2%
Valuation Rating
Overvalued
Estimated downside of 30.2%
Analyst Target
$6.28
Implied downside 1.9%
Financial Health
Good
Current financial-health read

The current fair value estimate for Lifecore Biomedical Inc (NASDAQ-LFCR) is $4.46. This implies an estimated downside of 30.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 30.2% versus the current market price.

The available analyst price target for Lifecore Biomedical Inc (NASDAQ-LFCR) is $6.28. The analyst target implies estimated downside of 1.9%.

The current financial health read for Lifecore Biomedical Inc (NASDAQ-LFCR) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Lifecore Biomedical Inc (NASDAQ-LFCR).

The current market capitalization listed for Lifecore Biomedical Inc is 242.4 M.

The current enterprise value listed for Lifecore Biomedical Inc is 432.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Lifecore Biomedical Inc is NASDAQ-LFCR, and the stock is listed on NASDAQ.

Lifecore Biomedical Inc (NASDAQ-LFCR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Lifecore Biomedical Inc is 35.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Lifecore Biomedical Inc is 51.1%. Free float helps investors understand how much of the share base is available for public trading.